US 11,883,509 B2
Pharmaceutical composition for inhalation administration for labeling pulmonary tumorous lesion, containing fluorescent contrast agent as active ingredient
Hyun Koo Kim, Seoul (KR); Yuhua Quan, Seoul (KR); Byeong-Hyeon Choi, Seoul (KR); Ji-Yun Rho, Incheon (KR); Ji Ho Park, Daejeon (KR); Ji Young Lim, Daejeon (KR); Chan Hee Oh, Daejeon (KR); and Daeho Jung, Daejeon (KR)
Assigned to Korea University Research and Business Foundation, Seoul (KR); and Korea Advanced Institute Of Science And Technology, Daejeon (KR)
Filed by KOREA UNIVERSITY RESEARCH AND BUSINESS FOUNDATION, Seoul (KR); and KOREA ADVANCED INSTITUTE OF SCIENCE AND TECHNOLOGY, Daejeon (KR)
Filed on Sep. 5, 2019, as Appl. No. 16/561,069.
Claims priority of application No. 10-2018-0106037 (KR), filed on Sep. 5, 2018; and application No. 10-2019-0108377 (KR), filed on Sep. 2, 2019.
Prior Publication US 2020/0101175 A1, Apr. 2, 2020
Int. Cl. A61B 17/00 (2006.01); A61K 49/00 (2006.01); A61K 9/00 (2006.01)
CPC A61K 49/0034 (2013.01) [A61K 9/0078 (2013.01)] 5 Claims
 
1. A method for selectively excising a damaged alveolar structure during surgery for pulmonary nodules, comprising:
(1) a step of administering a fluorescent contrast agent via respiration of a subject;
(2) a step of cutting open the chest of the subject and detecting a fluorescence signal generated by the contrast agent using a fluorescence imaging system; and
(3) a step of excising a region where the fluorescence signal is not detected, which is the damaged alveolar structure.